| Title: |
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample |
| Authors: |
Tognin, S; Vieira, S; Oliver, D; Cullen, AE; Kempton, MJ; Fusar-Poli, P; Mechelli, A; Dazzan, P; Merritt, K; Maat, A; de Haan, L; Lawrie, SM; van Amelsvoort, T; Arango, C; Nelson, B; Galderisi, S; Bressan, R; Kwon, JS; Mizrahi, R; Kawohl, W; Huber, N; Stämpfli, P; Burrer, A; Maatz, A; Kirschner, M; Furtner-Srajer, J; Weidenauer, A; Sauerzopf, U; Lenczowski, M; Willeit, M; Sachs, G; Lepock, J; Prce, I; Ahmed, S; Maheandiran, M; Gerritsen, C; Kiang, M; Weiser, M; Lho, SK; Moon, SY; Kim, M; Lee, TY; Cho, KIK; da Cunha, GR; Gadelha, A; Zugman, A; Patriarca, S; Pietrafesa, D; Piegari, G; Bucci, P; Mucci, A; McHugh, M; Amminger, P; McGorry, P; Sommer, J; Bitsch, F; Falkenberg, I; Kircher, T; Díaz-Marsá, M; Rodríguez-Jiménez, R; Janssen, J; Ayora, M; Díaz-Caneja, CM; Vingerhoets, C; Marcelis, M; Campforts, B; Krämer, B; Richter, A; Gruber, O; Finnegan, M; McLoughlin, J; Cannon, D; Hallahan, B; McDonald, C; Rostrup, E; Schæbel, H; Tangmose, K; Ebdrup, BH; Sørensen, ME; Glenthøj, B; Garcia-de la foz, VO; Suarez-Pinilla, P; Ayesa-Arriola, R; Setien-Suero, E; Tordesillas-Gutierrez, D; Crespo-Facorro, B; Schirmbeck, F; Winter, I; van Hell, E; Kahn, R; Spencer, T; De Micheli, A; Antoniades, M; Petros, N; Gifford, G |
| Publisher Information: |
Nature Research |
| Publication Year: |
2025 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The PSYSCAN project aimed to enhance predictive value by integrating data across clinical, environmental, neuroimaging, cognitive, and peripheral blood biomarkers. PSYSCAN employed a naturalistic, prospective design across 12 sites (Europe, Australia, Asia, Americas). Assessments were conducted at baseline, 3, 6, and 12 months, with follow-ups at 18 and 24 months to evaluate clinical and functional outcomes. The study included 238 CHR individuals and 134 healthy controls (HC). At baseline, CHR and HC groups differed significantly in age, education, IQ, and vocational and relationship status. Cannabis and tobacco use did not significantly differ between groups, however CHR individuals had higher proportion of moderate to high risk of tobacco abuse. A substantial portion of the CHR sample met DSM criteria for anxiety (53.4%) and/or mood disorders (52.9%), with some prescribed antidepressants (38.7%), antipsychotics (13.9%), or benzodiazepines (16.4%). Over the follow-up period, 25 CHR individuals (10.5%) transitioned to psychosis. However, the CHR group as a whole showed improvements in functioning and attenuated psychotic symptoms. Similar to other recent multi-centre studies, the CHR cohort exhibits high comorbidity rates and relatively low psychosis transition rates. These findings highlight the clinical heterogeneity within CHR populations and suggest that outcomes extend beyond psychosis onset, reinforcing the need for broader prognostic models that consider functional and transdiagnostic outcomes. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
2754-6993 |
| Relation: |
NHMRC/2026484; https://hdl.handle.net/11343/360524 |
| Availability: |
https://hdl.handle.net/11343/360524 |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; CC BY |
| Accession Number: |
edsbas.19EC453C |
| Database: |
BASE |